다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
생물정신의학 = Korean journal of biological psychiatry, v.28 no.2, 2021년, pp.50 - 57
김재원 (서울대학교병원 정신건강의학과) , 김세현 (서울대학교병원 정신건강의학과) , 장진혁 (블레스병원) , 문선영 (서울대학교병원 정신건강의학과) , 강태욱 (의정부을지대학교병원 정신건강의학과) , 김민아 (서울대학교병원 정신건강의학과) , 권준수 (서울대학교병원 정신건강의학과)
AI-Helper
Objectives Clozapine is the most effective atypical antipsychotic agent for the treatment-resistant schizophrenia (TRS), however, only 40%-70% of TRS patients respond to clozapine. Moreover, TRS encompasses various symptom dimensions. Therefore, augmentation with other medications for clozapine is f...
Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry 2007;18:39-60.
Kim SH. Current status of clozapine for treatment-resistant schizophrenia. Korean J Schizophr Res 2021;24:1-7
Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2016;209:385-392.
Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry 2017;174:216-229.
Lee JS, Yun JY, Kang SH, Lee SJ, Choi JH, Nam B, et al. Korean Medication Algorithm for Schizophrenia 2019, second revision: treatment of psychotic symptoms. Clin Psychopharmacol Neurosci 2020;18:386-394.
Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull 2010;36:94-103.
Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012;13:318-378.
Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M. Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry 2017;62:604-616.
Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia. Am J Psychiatry 2020;177:868-872.
Samanaite R, Gillespie A, Sendt KV, McQueen G, MacCabe JH, Egerton A. Biological predictors of clozapine response: a systematic review. Front Psychiatry 2018;9:327.
Lee K. Treatment-resistant schizophrenia: terminology and clinical features. Korean J Schizophr Res 2020;23:45-50.
Taylor DM, Smith L, Gee SH, Nielsen J. Augmentation of clozapine with a second antipsychotic - a meta-analysis. Acta Psychiatr Scand 2012;125:15-24.
Siskind DJ, Lee M, Ravindran A, Zhang Q, Ma E, Motamarri B, et al. Augmentation strategies for clozapine refractory schizophrenia: a systematic review and meta-analysis. Aust N Z J Psychiatry 2018;52:751-767.
Wagner E, Lohrs L, Siskind D, Honer WG, Falkai P, Hasan A. Clozapine augmentation strategies - a systematic meta-review of available evidence. Treatment options for clozapine resistance. J Psychopharmacol 2019;33:423-435.
Roerig JL. Clozapine augmentation strategies. Ment Health Clin 2019;9:336-348.
Bartoli F, Crocamo C, Di Brita C, Esposito G, Tabacchi TI, Verrengia E, et al. Adjunctive second-generation antipsychotics for specific symptom domains of schizophrenia resistant to clozapine: a meta-analysis. J Psychiatr Res 2019;108:24-33.
Tiihonen J, Taipale H, Mehtala J, Vattulainen P, Correll CU, Tanskanen A. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry 2019;76:499-507.
Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 2012;138:18-28.
Latimer E, Wynant W, Clark R, Malla A, Moodie E, Tamblyn R, et al. Underprescribing of clozapine and unexplained variation in use across hospitals and regions in the Canadian province of Quebec. Clin Schizophr Relat Psychoses 2013;7:33-41.
Xiang YT, Buchanan RW, Ungvari GS, Chiu HF, Lai KY, Li YH, et al. Use of clozapine in older Asian patients with schizophrenia between 2001 and 2009. PLoS One 2013;8:e66154.
Bachmann CJ, Aagaard L, Bernardo M, Brandt L, Cartabia M, Clavenna A, et al. International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand 2017;136:37-51.
Green AI, Canuso CM, Brenner MJ, Wojcik JD. Detection and management of comorbidity in patients with schizophrenia. Psychiatr Clin North Am 2003;26:115-139.
Yun JY, Lee JS, Kang SH, Nam B, Lee SJ, Lee SH, et al. Korean treatment guideline on pharmacotherapy of co-existing symptoms and antipsychotics-related side effects in patients with schizophrenia. Korean J Schizophr Res 2019;22:21-33.
Li XB, Tang YL, Wang CY, de Leon J. Clozapine for treatment-resistant bipolar disorder: a systematic review. Bipolar Disord 2015;17:235-247.
Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry 2010;167:686-693.
Inada T, Inagaki A. Psychotropic dose equivalence in Japan. Psychiatry Clin Neurosci 2015;69:440-447.
Wheeler AJ. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. Ann Pharmacother 2008;42:852-860.
Harrison J, Janlov M, Wheeler AJ. Patterns of clozapine prescribing in a mental health service in New Zealand. Pharm World Sci 2010;32:503-511.
Tungaraza TE, Ahmed W, Chira C, Turner E, Mayaki S, Nandhra HS, et al. Prescribing pattern of clozapine and other antipsychotics for patients with first-episode psychosis: a cross-sectional survey of early intervention teams. Ther Adv Psychopharmacol 2017;7:103-111.
Yi W, She S, Zhang J, Wu H, Zheng Y, Ning Y. Clozapine use in patients with early-stage schizophrenia in a Chinese psychiatric hospital. Neuropsychiatr Dis Treat 2020;16:2827-2836.
Verdoux H, Pambrun E. Clozapine use pattern in persons with and without treatment for Parkinson's disease in real-world conditions: a naturalistic study in a community-based sample. Acta Psychiatr Scand 2014;130:487-497.
Lally J, Ajnakina O, Di Forti M, Trotta A, Demjaha A, Kolliakou A, et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med 2016;46:3231-3240.
Bozzatello P, Bellino S, Rocca P. Predictive factors of treatment resistance in first episode of psychosis: a systematic review. Front Psychiatry 2019;10:67.
Kinon BJ. The group of treatment resistant schizophrenias. Heterogeneity in treatment resistant schizophrenia (TRS). Front Psychiatry 2019;9:757.
Singh A, Beniwal RP, Bhatia T, Deshpande SN. Prevalence and clinical correlations of obsessive-compulsive symptoms in schizophrenia. Asian J Psychiatr 2019;39:48-52.
Zheng W, Xiang YT, Yang XH, Xiang YQ, de Leon J. Clozapine augmentation with antiepileptic drugs for treatment-resistant schizophrenia: a meta-analysis of randomized controlled trials. J Clin Psychiatry 2017;78:e498-e505.
Wong J, Delva N. Clozapine-induced seizures: recognition and treatment. Can J Psychiatry 2007;52:457-463.
Poyurovsky M, Weizman A, Weizman R. Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment. CNS Drugs 2004;18:989-1010.
Sa AR, Hounie AG, Sampaio AS, Arrais J, Miguel EC, Elkis H. Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol. Compr Psychiatry 2009;50:437-442.
Spina E, Avenoso A, Salemi M, Facciola G, Scordo MG, Ancione M, et al. Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. Pharmacopsychiatry 2000;33:213-217.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.